At Investor Conferences

Advertisement

Picture ConsulTech GmbH GDPR-compliant E-Col Home Office 650x80px
Organisation › Details

Eyevensys S.A.S.

http://www.eyevensys.com
Link has been incorrect on 2013-12-09

Eyevensys is a privately held, clinical-stage biotechnology company developing its innovative technology to enable the sustained intraocular production of therapeutic proteins to treat a broad range of ophthalmic diseases. The Eyevensys technology, developed by Dr. Francine Behar-Cohen in Paris, uses electroporation to deliver improved proprietary DNA plasmids encoding therapeutic proteins into the ciliary muscle of the eye. This approach facilitates the sustained intraocular production of therapeutic proteins. Eyevensys' lead product EYS606 is a potential new treatment for patients with chronic non-infectious uveitis (NIU). EYS606 combines Eyevensys' proprietary Electrotransfection System with plasmids encoding for the production of a potent fusion protein which neutralizes the activity of TNFa, a cytokine that has been shown to play a pivotal role in mediating intraocular inflammation in NIU. EYS606 is currently in a phase I/II clinical trial in the EU and has been granted an Orphan drug designation by the European Medicines Agency (EMA) for the treatment of NIU. The therapeutic potential of EYS606 in patients with active, chronic NIU will be further investigated in Part 2 of the ongoing EYS606-CT1 study in the EU and in a second phase 2 trial, the Electro Study (EYS606-CT2) that will be launched in the US in early 2020. Additionally, Eyevensys is developing EYS611, a treatment for Retinitis Pigmentosa and Dry AMD. The treatment encodes for a potent iron chelator with antioxidant and endogenous neuroprotective properties. In animal models, the treatment has been shown to be safe and effective at preserving the retina in the wake of both conditions. Eyevensys is also advancing a third compound, EYS609, for wet AMD, diabetic macular edema, and central retinal vein occlusion, and it is exploring further compounds for undisclosed indications. Eyevensys was founded in 2008. It is headquartered in Paris, France, and operates a wholly-owned U.S. subsidiary out of Fort Worth, Texas. The company is funded by the Boehringer Ingelheim Venture Fund, Pureos Bioventures, Bpifrance through the Innobio Fund, CapDecisif, Inserm Transfert Initiative, Pontifax and the Global Health Sciences Fund. *

 

Period Start 2008-01-01 established
  Group Eyevensys (Group)
Products Industry gene therapy
  Industry 2 ophthalmic
Person Person Zilliox, Patricia (Eyevensys 201712– CEO joined board 201605 before Foundation Fighting Blindness + Alcon)
     
Region Region Paris
  Country France
  Street 11 rue Watt
Bât B
  City 75013 Paris
  Tel +33-1-8479-1060
    Address record changed: 2020-01-16
     
Basic data Employees A: 1 to 10 (2014-10-22)
     
    * Document for �About Section�: Eyevensys S.A.S.. (1/8/20). "Press Release: Eyevensys Closes $30M Series B Financing". Paris & Fort Worth, TX.
     
   
Record changed: 2020-01-16

Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px

More documents for Eyevensys (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

Picture ConsulTech GmbH Berlin Grant Application and Coordination 650x80px




» top